(Q68149114)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference

1 reference

Bergsagel DE

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

publication date

1 April 1988

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

159-166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy for multiple myeloma

22 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Colony growth and self renewal of plasma cell precursors in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900060216

7 January 2021

Identifiers

DOI

10.1002/HON.2900060216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3292373%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference